Verrica Pharma Files 8-K on Financials and Personnel
Ticker: VRCA · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $150,000, $300,000, $40,000, $40,500.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, management-changes, corporate-governance
TL;DR
Verrica Pharma dropped an 8-K detailing financials and exec changes. Check it out.
AI Summary
Verrica Pharmaceuticals Inc. filed an 8-K on November 4, 2024, reporting on results of operations and financial condition, as well as changes in directors and officers. The filing covers events up to November 1, 2024, and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on Verrica Pharmaceuticals' financial health and any significant changes in its leadership, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — The filing concerns financial results and potential changes in corporate governance, which can introduce uncertainty.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- November 1, 2024 (date) — Earliest event reported
- November 4, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 46-3137900 (tax_id) — IRS Employer Identification No.
- West Chester, PA (location) — Principal Executive Offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
Are there any new directors or officers appointed or departing?
Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of information.
What is the primary business of Verrica Pharmaceuticals Inc.?
Verrica Pharmaceuticals Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
When was Verrica Pharmaceuticals Inc. incorporated?
The company was incorporated in Delaware.
What is the principal executive office address for Verrica Pharmaceuticals Inc.?
The principal executive offices are located at 44 W. Gay St., Suite 400, West Chester, PA 19380.
Filing Stats: 2,575 words · 10 min read · ~9 pages · Grade level 10.5 · Accepted 2024-11-04 16:17:59
Key Financial Figures
- $150,000 — . The Company paid Pareto Partners, LLC $150,000 during 2023 for such services. There is
- $300,000 — r will receive an annual base salary of $300,000 per year, subject to review and adjustm
- $40,000 — Mr. Kirby will receive a monthly fee of $40,000. The term of the Services Agreement beg
- $40,500.00 — ock units (the " Kirby RSUs ") equal to $40,500.00 divided by the closing price of the Com
Filing Documents
- d907851d8k.htm (8-K) — 46KB
- d907851dex101.htm (EX-10.1) — 27KB
- d907851dex102.htm (EX-10.2) — 25KB
- d907851dex103.htm (EX-10.3) — 82KB
- d907851dex104.htm (EX-10.4) — 107KB
- d907851dex105.htm (EX-10.5) — 46KB
- d907851dex106.htm (EX-10.6) — 57KB
- d907851dex991.htm (EX-99.1) — 122KB
- g907851g1102085150877.jpg (GRAPHIC) — 3KB
- g907851g1105003011291.jpg (GRAPHIC) — 3KB
- 0001193125-24-250638.txt ( ) — 764KB
- vrca-20241101.xsd (EX-101.SCH) — 3KB
- vrca-20241101_lab.xml (EX-101.LAB) — 18KB
- vrca-20241101_pre.xml (EX-101.PRE) — 11KB
- d907851d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 Release Agreement, dated November 4, 2024, by and between the Company and Ted White 10.2 Offer Letter, dated November 4, 2024, by and between the Company and Jayson Rieger 10.3 Professional Services Agreement, dated November 4, 2024, by and between the Company and John J. Kirby 10.4 Verrica Pharmaceuticals, Inc. 2024 Inducement Plan 10.5 Form of Restricted Stock Unit Award Grant Notice and Award Agreement under 2024 Inducement Plan 10.6 Form of Stock Option Grant Notice and Stock Option Agreement under 2024 Inducement Plan 99.1 Press Release, dated November 4, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: November 4, 2024 /s/ Ted White Ted White President and Chief Executive Officer